G2019S selective LRRK2 kinase inhibitor abrogates mitochondrial DNA damage
Nicholas Pena, Tara Richbourg, Claudia P. González-Hunt, Rui Qi, Paul B. Wren, Carrolee Barlow, Natalie F. Shanks, Holly J. Carlisle, Laurie H. Sanders
The paper tests a G2019S selective LRRK2 inhibitor, EB-42168, showing it reduces mtDNA damage in G2019S models and patient cells better than a non-selective inhibitor.
npj Parkinson s Disease · Mar 1, 2024Peer-reviewedNeuroscience